赛诺菲及葛兰素史克药厂研发新冠疫苗次阶段测试显示能产生足够抗体
法国药厂赛诺菲(Sanofi)及英国药厂葛兰素史克(GSK)合作研发的新冠疫苗,於第二阶段进行的测试显示,测试者接种两剂疫苗後产生足够抗体及没有安全问题。药厂将在未来数周举行第三阶段临床测试,预期在今年第四季获药物监管当局批准使用。
药厂表示,於第二阶段测试的中期结果显示,在完成第二剂接种後出现95%至100%血清抗体转换反应,产生抗体水平与曾确诊者可比拟。研究有722名18至95岁志愿者参加,其中18至59岁志愿者的抗体水平较高。
第三阶段测试将邀请逾3.5万名成年人参与,并将测试疫苗对武汉所发现新冠病毒及南非变种病毒的反应。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.